dismiss

Our Clean Sweep Live Auction is coming up fast! Next Tuesday, September 26th at 9:30AM EST

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment

 

Molecular Imaging Homepage

United States molecular diagnostics market to reach $9 billion by 2024

Edinburgh Molecular Imaging commences phase II European cancer trial

SHINE Medical Technologies chooses QAD Cloud ERP to automate and streamline its financials

Molecular spectroscopy market to reach $6.85 billion by 2022

Cell marking opens up a window into the body

SHINE selects Baker Concrete Construction as prime contractor for medical isotope production facility project

Researchers double target ligands to identify and treat prostate cancer

Glowing cancer tool illuminates benign, but dangerous, brain tumors during pituitary surgery

Blue Earth Diagnostics announces initial results of Fluciclovine PET/CT impact on recurrent prostate cancer at ASTRO

Medical image analysis software market worth 3.88 billion by 2022

New possibility of studying how Alzheimer's disease affects the brain at different ages

Press releases may be edited for formatting or style
Alzheimer's disease can lead to several widely divergent symptoms and, so far, its various expressions have mainly been observed through the behaviour and actions of patients. Researchers at Lund University in Sweden have now produced images showing the changes in the brain associated with these symptoms - a development which increases knowledge and could facilitate future diagnostics and treatment.

Symptoms vary in cases of Alzheimer's disease and often relate to the phase of life in which the disease first occurs. People who become ill before the age of 65 often suffer early on from diminished spatial perception and impaired orientation. Elderly patients more often suffer the symptoms traditionally associated with the disease: above all, memory impairment.

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory DOTmed Certified



"Now we have a tool which helps us to identify and detect various sub-groups of Alzheimer's disease. This facilitates the development of drugs and treatments adapted to various forms of Alzheimer's", explains Michael Schöll, researcher at Lund University and the University of Gothenburg.

Diagnostics could also be facilitated, mainly among younger patients in whom it is particularly difficult to arrive at a correct diagnosis.

Confident in approval for clinical use

The findings, published in the journal Brain, are based on studies of around 60 Alzheimer's patients at Skåne University Hospital and a control group consisting of 30 people with no cognitive impairment.

Once Alzheimer's disease has taken hold, it gradually results in the tau protein, present in the brain, forming lumps and destroying the transport routes of the neurons. This can be clearly detected with the new imaging method.

The method includes a device known as a PET camera and a trace substance, a particular molecule, which binds to tau. The imaging method is currently only used in research, where the current study is one of several contributing to increased knowledge about the disease:

"The changes in the various parts of the brain that we can see in the images correspond logically to the symptoms in early onset and late onset Alzheimer's patients respectively", explains Oskar Hansson, professor of neurology at Lund University and consultant at Skåne University Hospital.

Oskar Hansson believes that the imaging method will be in clinical use within a few years.

The study was funded by the European and Swedish Research Councils, The Swedish Alzheimer foundation and ALF funding from Region Skåne, among others.

Footnote: The imaging method's technical designation is F-AV-1451 PET (Positron Emission Tomography)

Facts/Tau and beta-amyloid - illustrate different things in image analysis:

Tau analysis constitutes a new addition to Alzheimer's research, which was previously associated with the analysis of another protein in the brain, beta-amyloid. Both methods of analysis have their limitations.

For example, previous studies have shown that the connection between the various Alzheimer's symptoms and changes in the brain - which were investigated in the current study - cannot be visualised using beta-amyloid analyses.

However, for research into the earliest stages of Alzheimer's disease and its precursors, among other things, beta-amyloid studies have advantages and will continue to be important, in Oskar Hansson's assessment.

(Source: Lund University)

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED